Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) Interest & Investment Income (2016 - 2025)

Iovance Biotherapeutics has reported Interest & Investment Income over the past 7 years, most recently at $1.7 million for Q4 2025.

  • Quarterly results put Interest & Investment Income at $1.7 million for Q4 2025, down 81.83% from a year ago — trailing twelve months through Dec 2025 was $10.3 million (down 49.16% YoY), and the annual figure for FY2025 was $10.3 million, down 49.16%.
  • Interest & Investment Income for Q4 2025 was $1.7 million at Iovance Biotherapeutics, up from $1.2 million in the prior quarter.
  • Over the last five years, Interest & Investment Income for IOVA hit a ceiling of $9.6 million in Q4 2024 and a floor of $1.2 million in Q3 2025.
  • Median Interest & Investment Income over the past 3 years was $3.3 million (2024), compared with a mean of $3.6 million.
  • Biggest five-year swings in Interest & Investment Income: surged 207.09% in 2024 and later plummeted 81.83% in 2025.
  • Iovance Biotherapeutics' Interest & Investment Income stood at $3.1 million in 2023, then surged by 207.09% to $9.6 million in 2024, then plummeted by 81.83% to $1.7 million in 2025.
  • The last three reported values for Interest & Investment Income were $1.7 million (Q4 2025), $1.2 million (Q3 2025), and $4.1 million (Q2 2025) per Business Quant data.